Table 2. Demographics for the cohorts included in each of the four studies.
|
A. Mayo LOAD GWAS (Data Citation 2) |
B. Mayo eGWAS (Data Citations 3,4) |
C. Mayo Pilot RNAseq (Data Citation 5) |
||||||
|---|---|---|---|---|---|---|---|---|
|
TCX |
CER |
TCX |
||||||
| Variables | AD (n=844) | CON (1,255) | AD (n=202) | NON-AD (n=197) | AD (n=197) | NON-AD (n=177) | AD (n=94) | PSP (N=92) |
| Mean Age±s.d. (Range) | 74.0±4.8 (60–80) | 73.2±4.4 (60–80) | 73.6±5.5 (60–80) | 71.6±5.6 (60–80) | 73.6±5.6 (60–80) | 71.7±5.5 (60–80) | 74.1±5.7 (60–80) | 71.9±5.4 (60–80) |
| APOE4 positive/negative/null (%APOE4 positive) | 549/277/18 (65%) | 344/889/22 (27%) | 123/79/0 (61%) | 49/146/2 (25%) | 126/71/0 (64%) | 45/130/2 (25%) | 58/36/0 (62%) | 20/72/0 (22%) |
| Female (%) | 482 (57%) | 641 (51%) | 108 (53%) | 78 (40%) | 101 (51%) | 63 (36%) | 41 (44%) | 37 (40%) |
| Mean RIN±s.d. (Range) | NA | NA | 6.3±0.9 (5–9) | 6.9±1.0 (5–9.3) | 7.2±1.0 (5–9.4) | 7.2±1.0 (5–9) | 7.0±0.7 (6.2–9) | 7.0±0.9 (5.7–9.3) |
|
D. Mayo RNAseq (Data Citations 6,7) |
||||||||
|---|---|---|---|---|---|---|---|---|
|
TCX |
CER |
|||||||
| Variables | AD (n=84) | PSP (n=84) | Path Aging (n=30) | Control (n=80) | AD (n=86) | PSP (n=84) | Path Aging (n=28) | Control (n=80) |
| Mean Age±s.d. (Range) | 82.4±7.7 (60–90) | 74.0±6.5 (61–89) | 85.2±4.3 (76–90) | 82.6±8.8 (53–90) | 82.5±7.7 (60–90) | 74.0±6.5 (61–89) | 84.7±4.3 (76–90) | 82.5±8.3 (58–90) |
| APOE4 positive/negative (%APOE4 positive) | 43/41 (51%) | 13/71 (15%) | 10/20 (33%) | 10/70 (13%) | 43/43 (50%) | 13/71 (15%) | 9/19 (32%) | 11/69 (14%) |
| Female (%) | 48 (57%) | 33 (39%) | 17 (57%) | 39 (49%) | 49 (57%) | 33 (39%) | 16 (57%) | 39 (49%) |
| Mean RIN±s.d. (Range) | 8.6±0.5 (7.7–10.0) | 8.5±0.5 (7.8–10.0) | 7.4±1.0 (5.3–8.9) | 7.6±1.0 (5.3–9.7) | 8.3±0.8 (5.7–10.0) | 8.4±0.9 (5.5–10.0) | 7.5±1.0 (5.7–9.0) | 7.6±1.0 (5.5–9.7) |